GSK3174998: Phase I started

GlaxoSmithKline began an open-label, U.S. Phase I trial to evaluate 0.003-10 mg/kg IV GSK3174998 every 3 weeks for up to 48 weeks alone or with IV Keytruda pembrolizumab in about 264 patients. The fi...